FDA Meeting Types Decoded: What the Final PDUFA Formal Meetings Guidance Changes for Type D and INTERACT

A meeting with the U.S. Food and Drug Administration can decide the pace of a drug or biologic program. Ask for the wrong meeting type, submit an incomplete request, or misjudge the timeline, and months can slip. On 13 August 2026, FDA finalized the guidance that governs these meetings, and the update matters for any sponsor planning to engage the agency.

The final guidance clarifies the newer Type D and INTERACT meetings and describes the meeting formats FDA may grant. For Canadian companies taking a product into the United States, understanding the meeting framework is part of a sound regulatory strategy. This article explains what changed, walks through each meeting type and its timeline, and sets out what belongs in a complete meeting request.

What FDA changed

In short: FDA issued the final version of its formal meetings guidance. The Federal Register notice (91 FR 52305, document 2026-16452, docket FDA-2017-D-6530) announced the guidance on 13 August 2026. It finalizes the draft of the same title issued on 22 September 2023 and reflects agreements reached during the Prescription Drug User Fee Act (PDUFA) VII negotiations. The guidance applies to products regulated by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER).

FDA describes three substantive changes from the draft to the final guidance: additional scenarios for Type D meetings, clarification on Initial Targeted Engagement for Regulatory Advice on CDER and CBER products (INTERACT) meetings, and the addition of information on meeting formats that FDA may grant. Editorial changes were also made to improve clarity. The guidance sets out good meeting management practices and standardized procedures for requesting, preparing, scheduling, conducting, and documenting formal meetings.

The FDA meeting types at a glance

Why it matters: choosing the correct meeting type sets the timeline and the level of preparation FDA expects. The guidance describes several meeting types, each with its own purpose and its own scheduling goal measured from the date FDA receives the request. The table below summarizes them.

Meeting type	Typical purpose	FDA schedules within
Type A	A stalled program, or to resolve a dispute, address a clinical hold, or a special protocol assessment	30 days
Type B	Milestone meetings such as pre-IND, certain end-of-phase 1, and pre-NDA or pre-BLA	60 days
Type B (EOP)	End-of-phase 2 or pre-phase 3 meetings	70 days
Type C	Any other meeting about development and review that is not Type A, B, or B (EOP)	75 days
Type D	A narrow set of issues, a few disciplines, or a focused follow-up	50 days
INTERACT	Earliest advice for a novel product facing unique issues before the pre-IND stage	75 days

Type D meetings: narrow, fast, and now clearer

What it is: a Type D meeting is for a small, focused set of issues. It is meant for no more than a few questions that involve a limited number of disciplines, or for a targeted follow-up on a topic FDA and the sponsor have already discussed. FDA aims to schedule a Type D meeting within 50 days of receiving the request.

The final guidance adds scenarios that show when a Type D meeting fits. The practical value is speed. When you have a narrow question that could otherwise wait behind a broader Type C meeting, a well-scoped Type D request can get you an answer sooner. The discipline the sponsor must apply is restraint: keep the request narrow, because a Type D meeting loaded with too many topics may be reclassified or delayed.

INTERACT meetings: earliest advice for novel programs

What it is: INTERACT stands for Initial Targeted Engagement for Regulatory Advice on CDER and CBER products. It is the earliest formal engagement, intended for novel products and development programs facing unique challenges before the pre-IND stage, where existing guidance does not yet answer the question. FDA aims to schedule an INTERACT meeting or issue written responses within 75 days of receiving the request.

The clarification in the final guidance helps sponsors judge eligibility. INTERACT is not a substitute for a pre-IND meeting. It is for programs that are genuinely early and novel, for example a new technology, a first-in-class mechanism, or a complex manufacturing question with no clear precedent. Sponsors who use INTERACT well can surface a fundamental problem before they invest in a full development plan.

Meeting formats FDA may grant

How it affects your planning: the final guidance adds information on the meeting formats FDA may grant. In practice, FDA may hold a meeting by teleconference or video, in person, or in a hybrid format, or it may provide written responses only in place of a live meeting. Sponsors should prepare for the possibility that FDA answers in writing, because a written-response-only outcome still delivers the agency's advice and closes the meeting request. Build your questions so they can stand on their own in writing, not only in live discussion.

What goes in a meeting request and background package

What to do: submit a complete meeting request, then a focused background package. FDA states that the guidance gives industry the information needed to have a complete meeting request and background package, so the meeting produces useful feedback for product development. A request that is missing required elements can be delayed or returned, which resets your timeline. Key elements include:

Product and application details, and the proposed meeting type with the reason it fits.
A concise statement of the purpose and objectives of the meeting.
A short, prioritized list of questions, each tied to a specific discipline and a clear decision.
Proposed attendees for the sponsor, with their roles, and a proposed format.
A background package with just enough data and context to let FDA answer the questions, no more.

Why this matters for Canadian sponsors

Canadian pharmaceutical and biologics companies expanding into the United States rely on FDA meetings to de-risk development and review. Selecting the right meeting type, writing a complete request, and preparing a tight background package are exactly the tasks a strong regulatory affairs and licensing function should own. The same discipline that keeps a company inspection-ready in Canada, from clear documentation to a coherent regulatory strategy, carries across the border. If you already manage Canadian drug supply and reporting obligations, the FDA meeting framework is a natural extension of that work.

Compliance checklist

Use this checklist before you submit an FDA meeting request:

Define the single most important question the meeting must answer.
Select the correct meeting type: Type A, B, B (EOP), C, D, or INTERACT.
Confirm INTERACT eligibility if the program is early, novel, and lacks existing FDA guidance.
Confirm the product is a PDUFA product regulated by CDER or CBER.
Assemble a complete meeting request so it is not returned as incomplete.
Write a focused background package with a short, prioritized set of questions.
Map FDA's scheduling timeline for your meeting type and plan around it.
Prepare for the possibility that FDA answers in writing instead of holding a live meeting.
Document meeting outcomes and reconcile your notes against FDA's official minutes.

Common mistakes

Requesting a Type C meeting for a narrow question that a faster Type D meeting would have answered.
Treating INTERACT as a substitute for a pre-IND meeting when the program is not truly novel.
Overloading a Type D request with too many topics, which can trigger reclassification or delay.
Submitting an incomplete request, which resets the clock when FDA returns it.
Writing questions that only work in live discussion, then getting written responses that miss the point.

Frequently asked questions

What is a Type D meeting with FDA?

A Type D meeting is for a small, focused set of issues involving a limited number of disciplines, or a targeted follow-up. FDA aims to schedule it within 50 days of receiving the request. The 2026 final guidance adds scenarios showing when a Type D meeting is appropriate.

What is an INTERACT meeting?

INTERACT means Initial Targeted Engagement for Regulatory Advice on CDER and CBER products. It is the earliest formal engagement, for novel programs facing unique issues before the pre-IND stage. FDA aims to schedule it or provide written responses within 75 days of the request.

When did the final guidance take effect?

FDA announced the final guidance in the Federal Register on 13 August 2026 (91 FR 52305). Guidance documents represent FDA's current thinking on availability and are not legally binding, but they describe the procedures FDA expects sponsors to follow.

Does the guidance apply to biologics as well as drugs?

Yes. The guidance applies to products regulated by both CDER and CBER, which covers new drugs and biological products such as vaccines and cell and gene therapies within the PDUFA program.

Can I still comment on the guidance?

Yes. FDA accepts comments on any guidance at any time under 21 CFR 10.115(g)(5). There is no fixed closing date, and comments are submitted to docket FDA-2017-D-6530 on Regulations.gov.

How is this different from the 2023 draft?

The final guidance adds scenarios for Type D meetings, clarifies INTERACT meetings, and adds information on the meeting formats FDA may grant, along with editorial changes. It finalizes the draft issued on 22 September 2023 under docket FDA-2017-D-6530.

How MFLRC can help

MF License and Regulatory Consultants supports pharmaceutical and biologics companies on both sides of the border. We help sponsors choose the right FDA meeting type, build complete meeting requests and background packages, and prepare focused questions that hold up whether the meeting is live or answered in writing. Our regulatory affairs work spans submission strategy, gap assessments, SOP development, and quality systems, and it connects to the wider compliance picture, from FDA quality expectations to cross-border reliance and market access. Whether you are planning your first pre-IND meeting or a focused Type D follow-up, we can help you get more from every FDA interaction.

Planning an FDA meeting and not sure which type fits, or how to build the request? MFLRC can help you scope the meeting, prepare the package, and make the most of the agency's feedback.

Book a consultation with MFLRC

Conclusion

FDA's final formal meetings guidance does not reinvent the framework, but it sharpens it. The clearer treatment of Type D and INTERACT meetings, and the added detail on meeting formats, give sponsors more ways to get timely advice, if they choose the right meeting type and submit a complete request. For Canadian companies entering the United States, that clarity is an opportunity. Plan the meeting type early, keep the request focused, and prepare your questions to work in writing as well as in the room.